Myriad myPlan lung cancer test shows significant benefits in studies

Nov. 7, 2013

Myriad Genetics, Inc., has announced that validation data for its newly launched Myriad myPlan Lung Cancer test shows that the test significantly predicts patients’ risk of death from early-stage lung adenocarcinoma within five years of being diagnosed. A study found that patients with a high-risk myPlan prognostic score had approximately twice the number of lung cancer-related deaths as patients with a low-risk score. Myriad presented this result and another myPlan clinical study late last month as posters at the International Association for the Study of Lung Cancer (IASLC) 15th World Conference on Lung Cancer in Sydney, Australia.

The first poster presented at the IASLC meeting was “Validation of a Proliferation-based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma.” It evaluated the association of cell cycle progression (CCP) genes with five-year lung cancer mortality in 650 patients diagnosed with stage 1 or 2 lung adenocarcinoma. Patients with a high-risk Myriad myPlan Lung Cancer prognostic score had a significantly higher average five-year mortality rate (35%) than patients with a low-risk score (18%). View this poster.

The second poster, “Integrated Prognosis in Early-Stage Resectable Lung Adenocarcinoma,” evaluated a prognostic model that combines a CCP score with tumor stage in order to maximize the prognostic utility of both predictive markers. This study showed that the combination of tumor stage and the CCP expression score was a more powerful predictor of post-surgical risk of cancer-specific death than tumor stage alone. View this poster.